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1. Introduction 
Genes that affect a person's chance of developing hepatocellular carcinoma (HCC), as 
BRCA1 and BRCA2 affect a person's chance of developing breast or ovarian cancer, have 
been difficult to detect. The vast majority of liver cancers can be attributed to Hepatitis B or 
C virus infection, aflatoxin exposure, or alcoholic cirrhosis, alone or in combination 
(Montalto et al., 2002). This high background of predisposing environmental factors makes 
identifying less penetrant genetic contributors more difficult. Familial patterns of 
susceptibility to liver cancer independent of environmental factors have helped identify a 
few monogenic metabolic syndromes (e.g., hemochromatosis; Dragani, 2010). However, the 
analysis of liver tumors points to a variety of other genes that affect liver tumor 
development. The patterns of chromosome gain and loss in liver cancers worldwide reveal 
several regions that are gained or lost in up to 86% of tumors, including  gains of 1q, 6p, 8q, 
and 20q, and losses of 1p, 4q, 6q, 8p, 13q, 16q, and 17p (Lau and Guan, 2005; Chochi et al., 
2009; Zhang et al., 2010). Chromosome analyses combined with genome-wide association 
studies have revealed candidate HCC modifier genes for some of these regions, such as 
PAPSS1 on chromosome 4q and HCAP1 on chromosome 17p (Wan et al., 2004; Shih et al., 
2009).  
Mice present an independent model of liver carcinogenesis for which external variables such 
as chemical exposure can be controlled and the genetics is manipulable. Different inbred 
strains of mice develop cancers at different frequencies. Because these differences are 
genetic, and the mice are homozygous due to inbreeding, causative genes can be identified 
through positional cloning.  
Inbred mouse strains differ dramatically in their susceptibility to both spontaneous and 
carcinogen-induced HCC. Females of the C57BR/cdJ strain, for example, develop up to 50-
fold more tumors after a single injection of N,N-diethylnitrosamine (DEN) than females of 
the related, relatively resistant C57BL/6J (B6) strain. We have recently mapped the 
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predominant locus responsible for this difference to a 6 Mb region on Chromosome 17 
(Peychal et al., 2009). This region corresponds to part of the chromosome 6p region 
amplified in the majority of late-stage HCC (Santos et al., 2007; Chochi et al., 2009). 
The C3H/HeJ strain (C3H), highly susceptible to both spontaneous and carcinogen-induced 
HCC, develops up to 50-fold more liver tumors than the B6 strain after a single carcinogen 
treatment (Drinkwater and Ginsler, 1986). We previously reported mapping the 
predominant locus responsible for this susceptibility, Hcs7, to distal Chromosome 1 (Bilger 
et al., 2004). This chromosomal region corresponds in part to the 1q21-24 chromosomal 
region amplified in up to 86% of human liver cancers (Lau and Guan, 2005; Chochi et al., 
2009; Zhang et al., 2010). C3H alleles on mouse Chromosome 1 confer a dominant 15-fold 
increased susceptibility to male mice and a semi-dominant 5-fold increased susceptibility to 
female mice carrying C3H alleles (Bilger et al., 2004). 
Here we analyze the effect of C3H Chromosome 1 alleles on spontaneous hepato-
carcinogenesis, on apoptosis and mitosis after DEN treatment, and on preneoplastic lesion 
growth. We have mapped the Hcs7 modifier to a 3.3 Mb region and used expression and 
CGH arrays to identify the Ifi202b gene as a strong candidate for this locus. 
2. Materials and methods 
2.1 Mice 
B6 and C3H mice were purchased from the Jackson Laboratory (Bar Harbor, Maine) and 
bred in our facilities. All mice were housed in plastic cages on corncob bedding (Bed 
O’Cobs, Anderson Cob Division, Maumee, OH), fed Purina 5020 diet (9% fat; St. Louis, MO), 
and given acidified tap water ad libitum. Mice were inspected daily and weighed monthly. 
Lines derived from the B6.C3H-Ch1 recombinant strain (Bilger et al., 2004) were generated 
as follows. B6 females were mated with B6.C3H-Ch1 males heterozygous for the congenic 
region. Markers between D1Mit285 and D1MIT17 were used to identify recombinants, and 
breakpoints were mapped more finely with additional markers. Males and females from a 
given recombinant line were then intercrossed to generate homozygotes. Heterozygous or 
homozygous mice were mated with B6 to generate heterozygous experimental progeny 
(Figures 1 and 3, and Table 3) or homozygotes were intercrossed to generate homozygous 
experimental progeny (Tables 1 and 2). Tested parental B6.C3H-Ch1 were homozygous. 
Lines derived from B6.BR-Ch1 were generated by mating B6 females with B6.BR-Ch1 males 
heterozygous for the congenic region. The markers D1Mit143, D1Mit17,  and two additional 
microsatellite markers at 172.9 and 176.9 Mb were used to identify recombinants. (The lack 
of SNPs or SSLPs between B6 and BR in this region prevented refinement of these 
breakpoints.)  Heterozygotes were intercrossed to generate homozygous lines. B6 females 
were then crossed with homozygous congenic males to generate experimental progeny.  
The C3H.B6-Ch1 line carrying B6 alleles for distal Chromosome 1 on a C3H genetic 
background was generated by crossing C3B6F1 (N1) mice with C3H mice and selecting 
C3H.B6 N2 mice carrying B6 alleles at D1Mit143, D1Mit15, D1Mit166, and D1Mit461. 
Backcrossing to C3H and selection of these B6 alleles was continued for eight additional 
generations to generate C3.B6(D1Mit143-D1Mit461)N10, or "C3H.B6-Ch1" (Figure 3) mice. 
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2.2 Genotyping 
DNA was prepared from spleen tissue by Proteinase K treatment/ammonium 
acetate/isopropyl alcohol precipitation as described (Bilger et al., 2004) or from spleen, tail, 
or toe tissue by alkaline lysis (modified from Truett et al., 2000). Approximately 2 mm3 of 
spleen or 10 mm3 of tail or toe tissue was incubated in 200 µl lysis solution (25 mM NaOH, 
0.2 mM EDTA) at 95°C for 20-60 minutes and then neutralized by the addition of 200 µl 40 
mM Tris (pH 8.0). After agitation for approximately 30 seconds and centrifugation for five 
minutes at 13.5 krpm, 0.25 to 2 µl of the supernatant was used directly for genotyping as 
described (Bilger et al., 2004). 
2.3 Tumor and preneoplastic lesion induction and assessment 
Tumors were induced by a single intraperitoneal injection of DEN (Eastman Kodak Co., 
Rochester NY; 0.1 mol/g body weight) dissolved in tricaprylin (a.k.a. trioctanoin; Sigma, 
St. Louis, MO) 12 ± 1 days after birth. Mice, all male, were sacrificed by CO2 asphyxiation. 
For prenoplastic lesion volume analysis, mice were sacrificed at 16 or 24 weeks of age (Table 
2) and representative sections of the liver were frozen immediately on dry ice and stained 
for glucose-6-phosphatase activity as described (Bugni et al., 2001). Glucose-6-phosphatase 
deficiency is a hallmark of the majority of preneoplastic lesions in DEN-treated mice (Bugni 
et al., 2001). For tumor analysis, mice were sacrificed at 32 weeks of age (Figure 1, Figure 3). 
Livers were removed and weighed, and all tumors larger than 1 mm in diameter were 
counted. Liver tumors were sampled at random, fixed in RNAlater (Qiagen, Valencia, CA) 
at 4°C, then drained of RNAlater and transferred to -80°C. Spleens were collected as a 
source of DNA and frozen on dry ice. All tumors were scored by a single observer blind to 
genotype. To assess spontaneous tumors (Table 1), mice were allowed to age to 15 months 
without undergoing any procedures. Tumors larger than 1 mm in diameter were counted. 
To assess apoptosis, mitosis, and RNA expression immediately following DEN injection, 
male mice were either left untreated or injected with DEN (0.1 mol/g body weight), at 12 
days of age between 11 a.m. and 3 p.m..  Mice were sacrificed one, two, or three days later 
between 3 and 6 p.m.. One half of each left lobe and half of each half of the medial lobe were 
placed in formalin at 4°C. Half of the remaining parts of the left and medial lobes were 
placed in RNAlater at 4°C. The remaining portions of the left and medial lobes were frozen 
in pre-chilled tubes on dry ice and transferred to -80°C. 
Formalin-fixed tissue was sectioned and stained with hematoxylin and eosin (H&E). 
Hepatocytes, apoptoses, and mitoses were counted under 600× magnification.  
2.4 Microarray analysis of gene expression   
RNA was purified from 20-70 mg liver or liver tumor tissue  fixed in RNAlater using an 
RNeasy MIDI kit (Qiagen, Valencia, CA) as directed, except 50% ethanol, rather than 70% 
ethanol, was added to the homogenized lysate. Fluorescently labeled cDNAs were 
generated using Agilent Quick-Amp Labeling kits and hybridized in competition with a 
mixed-sex, whole-tissue liver cDNA control to Agilent Whole Mouse Genome arrays (Item 
#G4122F, Agilent, Santa Clara, CA). Arrays were scanned using an Agilent DNA Microarray 
Scanner G2505C.  
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2.5 Comparative genomic hybridization 
Genomic DNA from male spleens was prepared using a standard Proteinase K/ammonium 
acetate/isopropyl alcohol precipitation protocol as described (Bilger et al., 2004), except 
DNA was treated with RNase A, which was then precipitated with ammonium acetate 
before the final DNA precipitation. Genomic DNA of either line 1R5 or inbred C3H mice 
was then labeled and mixed with control genomic B6 DNA, for dual-color CGH, and 
hybridized to the MM 8_WG_CGH_1of8 chip. This array has 50-75 nucleotide probes spaced 
at an average of 650 bp, covering all of Chr 1 and Chr 2 through position 123959568. Results 
were analyzed by Nimblegen CGH Services, using the CGH-segMNT algorithm (Roche 
Nimblegen, Madison, WI). 
2.6 Statistical analysis 
The significance of differences between tumor multiplicity data sets was determined by the 
Wilcoxon rank-sum test, using Mstat software (version 5.4, McArdle Laboratory for Cancer 
Research; URL, http://www.mcardle.wisc.edu/mstat). All P-values were calculated on the 
basis of a two-sided test, except in the case of spontaneous tumorigenesis, for which we 
were testing the one-sided hypothesis that C3H alleles that increase DEN-induced tumor 
multiplicity also increase spontaneous tumor multiplicity. Differences between RNA 
expression data sets were evaluated with the limma software package (Smyth, 2004), using a 
moderated t-statistic followed by FDR correction.  
3. Results 
3.1 A dominant modifier on Chr 1, Hcs7, maps to a 3.3 Mb region between 175.35 and 
178.64 Mb 
To map the Chromosome 1 modifier to a smaller region, we crossed B6 mice with B6.C3H-
Ch1 congenic mice carrying Hcs7 susceptibility alleles on Chromosome 1. Mice that had 
undergone recombination in the susceptibility region were selected and then bred again 
with B6 mice to generate heterozygous progeny cohorts for phenotyping. Male progeny 
were injected with DEN at 12 days and sacrificed at 32 weeks of age. The median number of 
tumors developed by males of each recombinant line is shown in Figure 1, below.  
Most of the susceptibility conferred by Hcs7 can be mapped to the distal end of the 
chromosome. Lines carrying C3H alleles only distal of D1Mit143 at 165 Mb developed 5- to 
12-fold more tumors than B6 (line 1R28:  P < 10-7; line 1R33:  P < 10-6; line 1R42:  P < 10-5). For 
lines 1R28 and 1R33, the number of tumors developed was not significantly different from 
the number developed by the homozygous B6.C3H-Ch1 parental congenic line (1R28:   
P > 0.30; line 1R33:  P > 0.11).  
Six of the seven recombinant lines that carry C3H from D1Mit15 at 170 Mb to D1Mit17 at  
191 Mb near the telomere were highly susceptible. These six lines developed an average of 
eight times as many tumors as B6. The exception, line 1R5, carries this susceptibility region 
but was resistant (1R5 vs B6:  P > 0.35). Comparative genomic hybridization revealed a 
potential explanation. In the distal susceptibility region, line 1R5 differs from C3H at the  
5' end of the Ifi202b gene (Figure 2). While line 1R5 and C3H both carry polymorphisms that 
suggest duplication of part of this region relative to B6, line 1R5 also carries polymorphisms 
that reduce hybridization to the CGH probes relative to B6 and C3H. This effect could be 
due to deletion, rearrangement, or novel sequences. 
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Fig. 1. C3H liver cancer susceptibility alleles map to distal Chromosome 1.  
Male mice carrying C3H alleles on Chromosome 1 on a B6 genetic background were injected 
with DEN and liver tumors were counted at 32 weeks. The line designated B6.C31 refers to 
B6.C3H-Ch1. Regions inherited from B6 are shown in white; C3H regions are shown in 
black. Regions carrying a breakpoint between B6 and C3H alleles are shown in grey. The 
median tumor multiplicity and number of mice tested are shown to the right of each line. 
Lines that were significantly more susceptible than B6 are marked with a "+."  The positions 
of markers along Chromosome 1 are shown as tics below the position axis at the top of the 
figure. 
Two additional lines, derived from the susceptible 1R14 and 1R33 lines during the breeding 
of experimental progeny, suggested that Hcs7 lies in a 6.4 Mb region carrying Ifi202b. 
Although few mice were phenotyped (five per line), the results for each line were 
significant. Line 33a, like its parent, was significantly more susceptible than B6 (P < 10-3) and 
not significantly different from B6.C3H-Ch1 (P > 0.55). The distal breakpoint for line 1R33a 
is proximal of 179.3 Mb, suggesting that the minimal susceptibility region lies proximal of 
179.3 Mb. Line 1R14a, unlike its parental line 1R14, was resistant to hepatocarcinogenesis. 
The difference between the lines is the distal breakpoint between 172.9 and 173.0 Mb in line 
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1R14a, suggesting that the minimal susceptibility region is distal of 172.9 Mb. Together, the 
two sublines suggest that Hcs7 lies between 172.9 and 179.3 Mb.  
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Fig. 2. The homozygous line 1R5 genome differs from C3H at Ifi202b.  
Genomic DNA of either line 1R5 or inbred C3H was labeled and mixed with control 
genomic B6 DNA before hybridization to a chip carrying Chromosome 1 probes spaced  
650 bp apart. The log2 ratio of the mean of the intensity of the 1R5 or C3H signal (Test) 
relative to B6 is plotted. C3H is shown as a dashed grey line; the 1R5 recombinant is shown 
as a solid black line. 
Several other congenic lines that lacked the distal susceptibility region were significantly 
more susceptible than B6, developing three- to four-fold more tumors by 32 weeks (lines 
marked with plus signs, Figure 1; P < 10-3 for all). These lines and the closely related 
congenic lines that are as resistant as B6 reveal a complex pattern of possibly interacting 
modifiers along proximal Chromosome 1. Resistant line 1R50, for example, carries more 
C3H than sensitive line 1R12, but it carries less C3H than sensitive line 1R54 (1R50 vs B6:  
P > 0.06; vs R12: p < 10-2; vs 1R54:  p < 0.02). Similarly, the C3H region carried by resistant 
line 1R7 extends farther distally than the C3H region carried by sensitive line 1R43. 
However, the resistance of line 1R7 might be explained by a unique B6 genotype at the 
proximal end of Chromosome 1 (proximal of 74 Mb).  
To localize the distal Chromosome 1 liver cancer modifier further, we bred line 1R33 with B6 
and selected males with breakpoints in or near the region between 172.9 and 179.3 Mb 
(Figure 3). These mice were bred with B6 females to generate experimental progeny that 
were injected with DEN at 12 days; tumors were counted at 32 weeks.  
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Fig. 3. C3H liver cancer susceptibility alleles map to a 3.3 Mb region between 175.35 and 
178.64 Mb.  
Male mice were injected with DEN and liver tumors were counted at 32 weeks. "B6" and 
"C3" mice were inbred; lines beginning with a "1" or "2" were B6.C3 congenic mice carrying 
C3H Chromosome 1 alleles on a B6 genetic background; "B6.BR." lines carry BR Chromo-
some 1 alleles on a B6 genetic background; and the C3H.B6-Ch1 (C3.B6-Ch1) line carries B6 
Chromosome 1 alleles on a C3H background. Regions inherited from B6 are shown in white; 
C3H and BR regions are shown in black. Regions carrying a breakpoint between B6 and 
C3H alleles, or between B6 and BR alleles, are shown in grey. The median tumor 
multiplicity and number of mice tested are shown to the right of each line. Lines that were 
significantly more susceptible than B6 are marked with a "+."  The positions of markers 
along Chromosome 1 are shown as tics below the position axis at the top of the figure. 
Mice from line 2R16, which carries the smallest susceptibility region, developed 7-fold more 
tumors than B6 (P < 10-5; Figure 3). This line carries C3H from 172.9 to 178.64 Mb, 
confirming and narrowing the location of the distal modifier. Line 2R16 was derived from 
line 2R3, which carries an additional ~14 Mb of C3H alleles distal of 178.64 Mb. Like 2R16, 
2R3 was highly susceptible, developing 10-fold more tumors than B6 (line 2R3 vs. 2R16:  
P > 0.12; vs. B6:  P < 10-8). Line 2R8 has a larger congenic region than 2R16, extending up to 
7.5 Mb farther proximally and ~ 700kb farther distally. This line was also highly susceptible, 
developing more than 8-fold more tumors than B6 (P < 10-5). Together with the parental line 
1R33 (again highly significantly different from B6), these lines establish that the Hcs7 locus 
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confers a 7- to 10-fold increase in tumor multiplicity and lies between 172.9 and 178.64 Mb. 
This region carries 132 genes (www.ensembl.org; 8/2011). Line 2R7, which extends distally 
from 175.35 Mb, was also highly susceptible relative to B6, developing almost 9-fold more 
tumors (P < 10-5). In addition, line 2R7 is approximately 3-fold more susceptible than line 
2R5, which carries C3H alleles distal of 178.9 Mb (P < 0.02). Together with the 2R16 results 
that place Hcs7 between 172.9 and 178.64 Mb, these data suggest that Hcs7 lies in the 3.3 Mb 
between 175.35 and 178.64 Mb. This region carries 44 genes (www.ensembl.org; 8/2011). 
Again, the remaining lines suggest that the pattern of modifiers along the chromosome is 
complex. Lines 2R9 and 2R7 both carry C3H alleles to near the telomere and line 2R9 carries 
more C3H alleles than 2R7 proximally (their breakpoints differ by about 100 Kb), but line 
2R9 is resistant (2R9 vs B6:  P > 0.24). Similarly, the resistance of line 2R11 (2R11 vs. B6:   
P > 0.09), which, like line 2R9, was derived from sensitive line 2R3, together with the 
susceptibility of lines 2R2, 2R10, 2R15, 2R7, and 2R5, suggests there are additional modifiers 
both proximal to and distal of the 175.4 to 178.64 Mb minimal region. Alternatively, some 
lines may have undergone rearrangement in the susceptibility region.  
Recombination between B6 and C3H was suppressed in the minimal susceptibility region, 
between 175.4 and 178.4 Mb. No recombinants were observed among approximately 1350 
segregating progeny, although 24 would be expected. This difference is highly significant  
(P < 10-6). Recombination is frequently suppressed by chromosomal rearrangements such as 
inversions (Kirkpatrick, 2010). 
3.2 B6 alleles on distal Chr 1 are sufficient to suppress hepatocarcinogenesis on a 
C3H background 
To determine whether B6 Chromosome 1 alleles can confer resistance to a sensitive C3H 
background (as C3H alleles confer sensitivity to a resistant B6 background), we generated 
C3H.B6-Ch1 congenics using ten generations of backcrossing B6 to C3H, selecting B6 alleles 
on distal Chromosome 1 at each generation. Heterozygous and homozygous congenic males 
and control inbred C3H males were injected with DEN at 12 days of age and their tumors 
were counted at 32 weeks (Figure 3). While heterozygosity for B6 alleles had no effect on 
tumorigenesis (P>0.84), homozygosity caused a 3.8-fold reduction in tumor multiplicity 
(P<10-3). 
3.3 C57BR/cdJ alleles between 175.35 and 178.64 Mb do not confer susceptibility 
We have shown previously that distal Chromosome 1 carries a modifier that causes 5- to  
6-fold increased susceptibility in male C57BR/cdJ (BR) mice relative to B6 mice (Poole and 
Drinkwater, 1996; Bilger et al., 2004). To determine whether this Hcif2 (formerly Hcf2) 
modifier might involve the same locus that confers susceptibility to C3H, we used 
B6.BR-Ch1 congenic mice to derive mice carrying smaller congenic regions and counted 
their tumors at 32 weeks (Figure 3). The line carrying the largest BR region, B6.BR.R4, 
developed fewer tumors than B6 (though not significantly; P > 0.37). Similarly, lines 
B6.BR.R5A and B6.BR.R5B, which carry part of the minimal region and extend distally 
beyond 191 Mb (R5A) or proximally beyond 165 Mb (R5B), also developed the same number 
of tumors as B6 or fewer (P > 0.86 and P > 0.68, respectively). All three recombinant lines 
developed significantly fewer tumors than the parental B6.BR-Ch1 line (not shown; P < 0.03 
for all). These results indicate that Hcif2 is unlikely to lie in the 175.35 to 178.64 Hcs7 region. 
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3.4 Haplotype analysis of sensitive and resistant strains 
The CBA/J strain is a cousin to C3H. Like its relative, CBA/J is highly susceptible to liver 
tumorigenesis, and the dominant modifier mapped in crosses between CBA/J and B6 maps 
to distal Chromosome 1 (Bilger et al., 2004). Because these strains are likely to share a 
susceptibility allele, we generated a haplotype map of the minimal Hcs7 region in CBA 
using SNPs obtained through the Imputed SNP Database (Szatkiewicz et al., 2008). Only 
SNPs that could be determined with greater than 80% confidence were included (Figure 4). 
This map suggests that CBA is highly related to the C3H strain through most of the Hcs7 
region, confirming the likelihood that these two sensitive strains share one or more 
susceptibility alleles. 
 
174 176 178
Position (Mb)
C57BL/6J
C3H/HeJ
CBA/J
C57BR/cdJ
 
Fig. 4. Haplotype maps for the Hcs7 interval. 
Haplotypes were determined for each gene and intergenic region. B6 haplotypes are shown 
as tics above the bar. C3H haplotypes are shown as tics below the bar.  Haplotypes unique 
to CBA are shown as grey tics centered on the bar, while haplotypes unique to BR are 
shown as outlined tics centered on the bar. The starting position of each gene is shown as a 
tic above the position axis. 
3.5 C3H Chromosome 1 alleles increase spontaneous hepatocarcinogenesis 
To determine whether Hcs7 influences spontaneous as well as DEN-induced hepato-
carcinogenesis, homozygous male mice were aged to 15 months and tumors were counted 
(Table 1). B6.C3H-Ch1 males developed significantly more liver tumors than B6 males (one-
sided P < 0.01). The 4-fold higher multiplicity and the 2.5-fold higher incidence in this line 
closely resemble the higher multiplicity and incidence seen in inbred C3H males (P > 0.85). 
Similarly, line 1R33 males developed twice as many tumors and had 50% higher incidence 
than B6. The difference in tumor multiplicity was significant (one-sided P < 0.04). Males of 
the proximally congenic line 1R11, which developed approximately 3-fold more tumors 
than B6 when treated with DEN, had approximately 25% higher incidence and developed 
approximately 25% more spontaneous tumors than B6, but this difference was not 
significant (one-sided P > 0.18). This analysis of spontaneous tumor incidence indicates that 
the majority of the difference between C3H and B6 can be ascribed to alleles on 
Chromosome 1, including alleles in the Hcs7 region.  
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Line N Incidence Multiplicity 
B6 46 0.21 0.28 ± 0.58 
C3H 38 0.53 0.84 ± 1.10 
B6.C3H-Ch1 17 0.47 1.35 ±2.21 
1R33 31 0.35 0.65 ± 1.05 
1R11  44 0.25 0.34 ± 0.71 
Table 1. B6.C3H-Ch1 and 1R33 males are more susceptible to spontaneous liver tumors  
than B6. 
Inbred and recombinant male mice were left untreated to 15 months of age and liver tumors 
were enumerated. N, the number of mice per group. 
Many line 1R33 males developed severe skin disease. Twenty-eight males died or were 
euthanized prior to the 15-month time point (as compared to three B6, eight C3H, ten 
B6.C3H-Ch1, and eight line 1R11 males). These line 1R33 males developed skin problems 
with a frequency that differed from both B6 and the B6.C3H-Ch1 line, suggesting that 
multiple cooperating genes along Chromosome 1 must be derived from the same strain to 
prevent skin lesions. Ifi202b and neighboring genes have been implicated in autoimmune 
skin disease in distal Chromosome 1 congenic lines derived from B6 and the NZB (New 
Zealand Black) strain (Choubey et al., 2010; Panchanathan et al., 2011). 
3.6 Hcs7 affects early lesion growth 
To determine when Hcs7 influences tumorigenesis, we measured preneoplastic lesion size 
in B6, C3H, and congenic lines that had been treated with DEN at 12 days of age. Livers 
were collected at 16 and 24 weeks and frozen immediately on dry ice, followed by 
glucose-6-phosphatase staining to identify preneoplastic lesions. In the first experiment, 
lesions were measured in B6, line 1R11, and line 1R33 livers. By sixteen weeks, lesions in 
the moderately susceptible line 1R11 and the highly susceptible line 1R33 occupied  
3.5 and 3.4 times, respectively, the volume occupied by B6 lesions (P < 10-3 for both lines; 
Table 2). At 24 weeks, 1R11 lesions occupied 1.5-fold more volume than B6 lesions  
(P > 0.15), while 1R33 lesions occupied 2.0-fold more volume than B6 lesions (P < 0.05). 
This result indicates that the growth advantage of lesions in the congenic lines begins 
prior to 16 weeks.  
A second experiment yielded results for line 2R8 that were very similar to those obtained for 
the larger 1R33 congenic. Line 2R8 lesions occupied 3.4-fold more volume than B6 lesions at 
16 weeks; the ratio was 3.3-fold at 24 weeks. This result confirms that Hcs7 modifies 
preneoplastic lesion growth. This second experiment included C3H males, which developed 
lesions that occupied significantly more volume than the congenic at both time points  
(16 wks:  P < 0.01; 24 wks:  P < 10-4). C3H lesions occupied 17-fold more volume than B6 at 
16 weeks, which increased to 33-fold more than B6 at 24 weeks. The magnitude of the 
growth effects in inbred C3H males suggests that Hcs7 C3H alleles are not sufficient to 
recapitulate entirely the early lesion development seen in C3H inbred mice. 
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Experiment/age N 
Focus Volume  
Fraction (VF) ± SD  
VF ratio 
Experiment 1    
16 weeks    
B6 14 0.00098 ± 0.0011 - 
1R33 19 0.0033 ± 0.0020 3.4 
1R11 10 0.0034 ± 0.0022 3.5 
24 weeks    
B6 18 0.022 ± 0.029 - 
1R33 12 0.043 ± 0.040 2.0 
1R11 9 0.033 ± 0.040 1.5 
Experiment 2    
16 weeks    
B6 13 0.00071 ± 0.00062 - 
2R8 12 0.0024 ± 0.0016 3.4 
C3H 12 0.012 ± 0.011 17 
24 weeks    
B6 12 0.0042 ± 0.0042 - 
2R8 12 0.014 ± 0.012 3.3 
C3H 11 0.14 ± 0.093 33 
Table 2. Distal Chromosome 1 alleles influence net lesion growth before 16 weeks. 
Male mice were treated at 12 days of age with DEN and sacrificed at 16 or 24 weeks of age. 
Frozen liver sections were evaluated for the presence and size distribution of glucose-6-
phosphatase-deficient foci. N, number of animals per group; VF ratio, volume fraction ratio 
relative to B6. 
3.7 Hcs7 does not modify apoptosis or mitosis in the acute response to DEN injection 
Other modifiers of DEN-induced hepatocarcinogenesis, such as IL-6 and IKKgamma, 
have been shown to affect apoptosis and/or mitosis within 72 hours of DEN 
administration (Maeda et al., 2005; Naugler et al., 2007). To determine whether the tumor 
susceptibility conferred by the Hcs7 region affects mitosis or apoptosis rates during this 
acute response to DEN injection, we collected livers from line 2R8 males one, two, or three 
days after DEN injection at 12 days of age. Livers were fixed in formalin and stained with 
H&E. Mitoses and apoptoses were scored based on staining and morphology, under  
600× magnification. Two microscopic fields centered on a portal vein and two fields 
centered on a central vein were scored. Hepatocytes were counted for 10-25 fields per 
strain and condition (e.g., B6/DEN). Each field represented an equivalent number of 
hepatocytes per field (~330) in resistant and susceptible mice, independent of DEN 
treatment (P > 0.07 for all comparisons). 
Rates of mitosis and apoptosis never differed significantly between B6 and line 2R8, whether 
or not mice were treated with DEN (P > 0.10 for all comparisons; Table 3). These results 
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indicate that the tumorigenic effect of Hcs7 does not involve acute changes in the rates of 
apoptosis or mitosis in response to DEN injection. 
 
  Num. mice  Mitoses / field  Apoptoses / field 
Age Treatment B6 2R8  B6 2R8  B6 2R8 
13 days No DEN 7 11  1.50 1.25  0.50 0.50 
14 days No DEN 9 9  2.00 1.5  0.25 0.50 
15 days No DEN 7 8  1.40 1.00  0.30 0.25 
13 days DEN 7 7  0.5 0.5  0.30 0.25 
14 days DEN 9 11  2.25 2.50  0.25 0.50 
15 days DEN 7 12  2.00 1.85  0.50 0.55 
Table 3. Mitosis and apoptosis do not differ significantly between line 2R8 and B6 during 
tumor initiation. 
3.8 The Hcs7-interval genes most differentially expressed between C3H and B6 are 
immune genes 
To identify potential candidate genes and pathways regulated by the Hcs7 region, we 
collected livers from DEN-treated B6 and 2R8 mice at 13 days, 28 hours after DEN injection. 
RNA from these livers was reverse-transcribed and hybridized to Agilent whole-genome 
arrays, in competition with a B6 mixed-sex control, to identify differentially expressed 
genes. These arrays carry 43,379 probes representing most genes in the genome. Of the 44 
genes in the 175.35 to 178.64 Mb region, 35 are represented by probes. The remaining nine 
include genes for three spliceosomal RNAs, two olfactory receptors, one protein of 
unknown function, and three pyrin-domain-containing genes. Genome-wide, Ifi202b is the 
only significantly differentially expressed transcript based on FDR correction (q < 10-2). The 
expression of Ifi202b is 57-fold higher in line 2R8 than in B6.  
To identify potential candidates that may not be expressed at 13 days, RNA from three B6 
and three 2R8 tumors was reverse transcribed and hybridized individually in competition 
with the mixed-sex control DNA. Genome-wide, Ifi202b was again the only significantly 
differentially expressed transcript, with levels 48-fold higher in 2R8 tumors than in B6 
tumors (genome-wide FDR q < 0.05). When limiting analysis of the expression array data set 
to only the 35 candidate genes in the 175.35 to 178.64 Mb minimal region, both Ifi202b and 
the closely related Aim2 (Absent in melanoma 2) were expressed at significantly different 
levels (q < 10-4 and q < 10-2, respectively). 
Recent resequencing of the C3H genome has revealed many SNPs in the Hcs7 region. Data 
compiled by the Mouse Genome Database (MGD) at the Mouse Genome Informatics 
website (Blake et al., 2011; URL: http://www.informatics.jax.org; 8/2011) show that the 
C3H alleles of eight genes in the Hcs7 region encode amino acids that differ from B6. Ifi202b 
carries a Thr/Ser polymorphism. The most dramatic changes lie in Mndal, which carries 
Arg/Gly and Asp/Tyr polymorphisms. Other genes in the interval with non-synonomous 
SNPs include Olfr433, Olfr419, Olfr220, Fmn2, Chml, and Exo1. 
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4. Discussion 
The Chromosome 1 liver cancer modifier Hcs7 has been localized to a 3.3 Mb region on 
distal Chromosome 1. In DEN-treated mice, the C3H allele of Hcs7 bred onto a resistant B6 
background confers 3- to 7-fold greater tumor multiplicity, dominantly. Consistent with 
these results, the B6 allele of Hcs7 bred onto a susceptible C3H background confers 4-fold 
resistance, recessively. Importantly, C3H alleles on Chromosome 1 including Hcs7 confer 
susceptibility to spontaneous tumorigenesis that is comparable to the susceptibility of 
inbred C3H mice. The Chr 1 hepatocarcinogenesis susceptibility allele in C57BR/cdJ mice, 
Hcif2, does not appear to correspond to Hcs7. B6.BR mice congenic for BR alleles distal of 
170 Mb are not more susceptible to liver tumorigenesis than B6 mice. 
The initiation of tumors after DEN injection is thought to involve the proliferation of DEN-
mutated hepatocytes in response to DEN-induced cell death, within 72 hours of injection 
(Maeda et al., 2005). We found that Hcs7 affects neither apoptosis nor mitosis in this time 
period. We have previously shown that preneoplastic lesions in inbred C3H males grow 
faster than B6 lesions, and that this differential growth can be seen from prior to 16 weeks 
until at least 28 weeks of age (Hanigan et al., 1988). Here, we show that Hcs7 accounts for 
part of this early growth advantage:  the volume of preneoplastic lesions in the B6.C3H 
congenic lines 1R33 and 2R8 is greater than for B6 lesions by 16 weeks and remains so at 24 
weeks. Our results indicate that Hcs7 begins to affect cell proliferation after the acute 
reaction to DEN injection and likely tumor initiation, but before 16 weeks, to promote lesion 
growth. 
The 175.35 to 178.64 Mb minimal interval carries 44 genes, of which 12 are related pyrin-
and/or p200-domain-containing interferon-gamma response genes such as Ifi202b, Aim2, 
and Mnda. Two additional genes encode proteins that are known or likely to mediate 
immune responses (Exo1 and the Crp-like gene 1810030J14Rik). This region also contains the 
cytoskeletal/cell polarity gene Fmn2 that is overexpressed in B-cell leukemias, a renal cell 
cancer tumor suppressor (Fh1), four known or likely signaling protein genes, and 14 
olfactory receptor genes.  
Ifi202b is a strong candidate for the HCC modifier gene in the Hcs7 locus. It was the only 
gene significantly differentially expressed on a genome-wide basis between B6.C3HHcs7 
congenics and B6 mice at 13 days of age (in the presence and absence of DEN) and in tumors 
from 32-week-old males. Importantly, CGH analysis indicates that the 5' end of Ifi202b is 
altered in the resistant B6.C3H congenic line 1R5, though the effect of this alteration on the 
protein or its expression still needs to be established. Finally, Ifi202b lies in the minimal 
susceptibility region determined by congenic lines, between 175.35 and 178.64 Mb. An 
important test of its candidacy will be to determine whether the CBA inbred strain, closely 
related to C3H and similarly susceptible to liver tumors, also expresses high levels of Ifi202b. 
When only genes in the minimal susceptibility region were evaluated for differential 
expression in tumors, Aim2 was the only other significantly differentially expressed gene. 
Aim2 is an interferon-regulated pro-apoptotic protein that is closely related to, can hetero-
dimerize with, and affects the expression of Ifi202b (Panchanathan et al., 2010; Choubey et 
al., 2010). Aim2 is a component of inflammasomes that sense cytoplasmic double-stranded 
DNA and activate caspase 1, which in turn activates IL1-β and induces inflammation 
(Fernandes-Alnemri et al., 2009; Bürckstümmer et al., 2009). 
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In transfected macrophage cell lines, Ifi202b overexpression reduces Aim2 expression, and 
Aim2 knock-down increases Ifi202b expression (Panchanathan et al., 2010). Similarly, Aim2 
null mice overexpress Ifi202b in spleen tissue. Absence of Aim2 expression correlates with 
cell growth in vitro and with cell immortalization in vitro, and Aim2 is inactivated in 
approximately half of colon cancers with microsatellite instability (Woerner et al., 2007; 
Choubey et al., 2010). Therefore, high levels of Ifi202b may prevent Aim2 expression and 
induce growth. Both Aim2 and Ifi202b were overexpressed in line 2R8 tumors relative to B6 
tumors. This result may reflect a tumor-specific response, as 13-day-old line 2R8 mice did 
not express more Aim2 than B6 mice. 
The high expression of Ifi202b in line 2R8 mice relative to B6 might reflect promoter and/or 
enhancer polymorphisms in both Aim2 and Ifi202b. The NZB allele of Ifi202b has been shown 
to be more active than the B6 allele, most likely due to a TATA-box-creating polymorphism 
in the NZB Ifi202b promoter (Choubey et al., 2010). Analysis of congenic lines suggests that 
B6-specific polymorphisms, conversely, enhance the expression of Aim2. Autoimmune-
sensitive congenics carrying NZB alleles from 154.7 to ~194 Mb express high levels of Ifi202b 
mRNA and protein relative to B6. However, mice from a line that carries a smaller NZB 
congenic region between approximately 174.5 to 194 Mb – including the entire Aim2 gene at 
175.2 Mb and the entire Ifi202b gene at 175.9 Mb – are not predisposed to autoimmunity. 
These resistant congenic mice express more Aim2 mRNA and protein and less Ifi202b mRNA 
and protein than the larger congenic. Indeed, levels of Ifi202b protein are similar to those of 
B6 mice (Panchanathan et al., 2010). The breakpoint between B6 and NZB alleles in this 
smaller congenic lies less than one megabase proximal of Aim2. The effect of B6 
polymorphisms near the 5' end of the Aim2 gene on Aim2 expression and, indirectly, Ifi202b 
expression may also explain the resistance to hepatocarcinogenesis of line 2R9. Assessing 
Aim2 and Ifi202b mRNA and protein levels in lines 2R8, 2R16, 2R9, and 2R7 would address 
this hypothesis.  
Interferon-inducible p200 family members have been shown to interact functionally with 
p53, MyoD, and Rb and appear to regulate proliferation, differentiation, apoptosis, and 
senescence (Gariglio et al., 2011). Overexpression of Ifi202b in particular has been shown to 
promote cell survival, while lower levels of expression increase cell death (Roberts et al., 
2009; Choubey et al., 2010). The expression of Ifi202b is upregulated by IL-6, which has been 
shown to be virtually required for hepatocarcinogenesis in DEN-treated mice, and Ifi202b 
can stimulate or inhibit the transcription of NFκB target genes depending on cell type 
(Naugler et al., 2007; Choubey et al., 2010). Given these many cell regulatory functions and 
its effect on Aim2 expression, Ifi202b could promote lesion growth in multiple ways. 
Determining whether preneoplastic cells in lines carrying C3H alleles undergo less cell 
death, an increase in mitosis, or both, will be an important first step in assessing the 
oncogenicity of Hcs7. 
Based on genome-wide analysis, no genes other than Ifi202b were significantly differentially 
expressed. However, nine genes were not represented on the expression array. These 
include several unlikely candidates (olfactory receptors and splicing RNAs that are found 
throughout the genome), as well as the pyrin/p200 proteins BC094916, Pydc3, and Mndal. 
The expression of these genes and the effect of amino acid changes in genes in the region 
will need to be evaluated. Finally, the test of Ifi202b as a candidate will require its over-
expression (e.g., from a transgene) in B6, or its disruption in C3H. 
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If Ifi202b is the molecule responsible for promoting hepatocarcinogenesis in mice carrying 
C3H Hcs7 alleles, it would make a tempting target for pharmacological intervention. The 
Hcs7 region corresponds to parts of human chromosome 1q22-23.1 and 1q43. Chromosome 
1q, including these regions, is amplified in 58% to 86% of human hepatocellular carcinomas, 
independent of stage (Thorgeirsson and Grisham, 2002; Lau and Guan, 2005; Chochi et al., 
2009; Zhang et al., 2010). When only parts of 1q are amplified, 1q22-23 is frequently affected. 
These observations imply that chromosome 1q alterations are an early event in 
hepatocarcinogenesis. Chromosome 1q is also frequently amplified in other liver cancers 
such as hepatoblastoma, cholangiocarcinoma, and fibrolamellar carcinoma, as well as 
cancers of other tissues such as the pancreas and the breast (Buendia, 2002; Climent et al., 
2002; Birnbaum et al., 2011; Ward and Waxman, 2011). Humans have four homologs of 
Ifi202b in the 1q22-23.1 region, including an ortholog of Aim2, an ortholog of Mnda, Ifi16 and 
IfiX/Pyhin1 (www.ensembl.org; 9/2011; Gariglio et al., 2011). All of these genes have been 
implicated in growth suppression in cell lines and ectopic tumor models; however, Ifi16 in 
particular is also associated in vivo with rapidly dividing epithelium and with undiffer-
entiated tissue including fetal hepatocytes and hepatocytes following liver transplantation 
(Gariglio et al., 2011). In an analysis of gene expression in a human tumor carrying a 1q 
amplification, four chromosome 1 genes were overexpressed. Only two of these correspond 
to mouse Chromosome 1: Mnda and "interferon-gamma inducible gene" at 1q22 (Ifi16 or IfiX; 
Niketeghad et al., 2001). All four Ifi p200 human genes express transcripts that encode both 
the pyrin cell death and p200 protein interaction domains (www.ensembl.org; 9/2011). Each 
also expresses transcripts that carry only one of the domains, and Ifi16 in particular 
expresses transcripts that carry only the pyrin domain, only the p200 domain, or both. These 
many alternative transcripts suggest the possibility that one of them is orthologous to 
Ifi202b, which expresses only the p200 domain. An analysis of human tumors should reveal 
which p200 family transcripts they express. Transgenesis could then be used to test the 
oncogenicity of these selected transcripts.  
C3H alleles from several regions of mouse Chromosome 1 conferred some significant 
susceptibility to B6 mice. Similarly, several regions on human chromosome 1 are amplified, 
sometimes simultaneously but separately, in human tumors (Lau and Guan, 2005; Chochi et 
al., 2009). It seems likely that multiple genes on Chromosome 1 in both mice and humans 
affect hepatocarcinogenesis.  
5. Conclusion 
We have mapped the mouse Hcs7 liver cancer modifier to a 3.3 Mb region on distal Chromo-
some 1 that carries 44 genes, of which many are involved in responding to immune stimuli.  
This region corresponds to human chromosome 1q22-23.1, which is amplified in most 
hepatocellular carcinomas. Ifi202b is a strong candidate gene for the Hcs7 modifier. Further 
study of the effect of its overexpression or disruption in vivo on short-term proliferation or 
apoptosis and long-term hepatocarcinogenesis will help establish whether its possible 
functional equivalent on human chromosome 1q is a worthy target for pharmacological 
intervention.  
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